Lunai Bioworks Secures First Revenue Defense Contract, Files Naked Shorting Suit Citing 29.6M FTDs
Summary
Lunai Bioworks announced its first revenue-generating, multi-year defense contract with BioSymetrics for AI-enabled chemical threat assessment. Concurrently, the company filed a lawsuit alleging naked short selling and is seeking expedited discovery, citing evidence of 29.6 million failing-to-deliver shares. This is a critical development for a company that has recently issued a "going concern" warning and undergone a reverse stock split to maintain Nasdaq compliance. The new defense contract provides a crucial revenue stream, addressing a fundamental financial risk. The alleged 29.6 million FTDs represent a value significantly exceeding the company's ~$18 million market capitalization, suggesting potential market manipulation and a highly volatile trading environment if the allegations are substantiated. The progress of the lawsuit and further details on the defense contract's financial terms will be key to watch.
At the time of this announcement, LNAI was trading at $4.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $18.1M. The 52-week trading range was $1.21 to $31.04. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.